United States

Aveo Oncology to restructure, cut workforce 62%

Friday, June 7, 2013 01:47 PM

Aveo Oncology, a cancer therapeutics company, is restructuring to refocus its efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advance key pipeline and preclinical assets. This restructuring is expected to extend the company's cash runway for at least two years, beyond anticipated data read-outs from ongoing trials of tivozanib and AV-203.

More... »

LLS, Dana-Farber partner to bring clinical trials to local communities

Friday, June 7, 2013 01:29 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency, joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.

More... »

Pfizer, UCSF partner to expand drug discovery capabilities

Thursday, June 6, 2013 10:22 AM

Pfizer has expanded its Centers for Therapeutic Innovation (CTI), which is dedicated to establishing partnerships with academic medical centers, into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF). This partnership provides investigators from UCSF with access to Pfizer's small-molecule drug development capabilities, working with Pfizer scientists with the goal of jointly translating basic research into drug candidates to bring new therapies to patients.

More... »

Maxygen board to dissolve, liquidate company

Wednesday, June 5, 2013 01:42 PM

The board of biopharmaceutical company Maxygen has approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other obligations of the company. Maxygen currently estimates the initial liquidating distribution to stockholders will be between $68.2 million and $69.6 million, or $2.45 to $2.50 per share.

More... »

MJFF launches $10 million programs for Parkinson’s research

Wednesday, June 5, 2013 01:40 PM

Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD).

More... »

Sanford-Burnham, Pfizer collaborate to speed drug discovery

Wednesday, June 5, 2013 01:18 PM

Sanford-Burnham Medical Research Institute has partnered with Pfizer as part of Pfizer's focus on translational medicine. The Centers for Therapeutic Innovation (CTI) is Pfizer’s research unit dedicated to establishing global partnerships with academic research institutions.

More... »

HealthCarePoint pledges $10 million in technology services to support ACRES

Tuesday, June 4, 2013 03:03 PM

HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking technology corporation, is pledging more than $10 million in technologies and infrastructure services to ACRES, the Alliance for Clinical Research Excellence and Safety, a Cambridge-based nonprofit organization established to develop a global system for improving quality, safety, ethics and operational effectiveness in drug development and health research.

More... »

Chiltern promotes Alecia Barbee to VP, Global Biometrics

Tuesday, June 4, 2013 12:00 PM

Global CRO Chiltern International has promoted Alecia Barbee to VP, Global Biometrics.

More... »

Armada names EVP of industry relations & advocacy

Monday, June 3, 2013 04:10 PM

Armada Health Care, a group purchasing and channel management organization for the specialty pharmacy market, has appointed Mike Baldzicki—EVP of industry relations & advocacy.

More... »

UPM purchases Pfizer commercial manufacturing site

Monday, June 3, 2013 11:32 AM

UPM Pharmaceuticals, a Baltimore, Md.-based drug development and contract manufacturer, will acquire the 500,000-square-foot commercial manufacturing facility Pfizer currently operates in Bristol, Tenn.

More... »